GlassScriptPhysician profile
Macaela Cirish
NPI 1558886671
$5,296.35
in general payments reported to CMS, 2019-2025
27 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $173 · 2023: $1,812 · 2024: $2,015 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,878 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,878.40 |
| Education | $106.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.65 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $648.23 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $594.28 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $505.17 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $299.81 | 2022-2025 | Epclusa |
| Celgene Corporation | $299.26 | 2023-2024 | Zeposia |
| Janssen Biotech, INC. | $283.40 | 2023-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $227.13 | 2023-2025 | |
| Lilly USA, LLC | $191.44 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $122.06 | 2021 | |
| Intercept Pharmaceuticals, INC. | $94.03 | 2023-2024 | Ocaliva |
| Qol Medical, LLC | $89.61 | 2023-2024 | Sucraid, Sucraid |
| Ferring Pharmaceuticals INC. | $76.61 | 2023-2024 | Rebyota |
| Novo Nordisk INC | $75.73 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $68.06 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $60.99 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $56.35 | 2022-2023 | |
| Celltrion USA INC. | $54.28 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $46.51 | 2023-2024 | Sutab, Suflave |
| Vivus LLC | $45.58 | 2025 | Pancreaze, Qsymia |
| Pfizer INC. | $34.08 | 2021-2024 | |
| Evoke Pharma, INC. | $29.27 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $28.31 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $25.63 | 2024 | Cologuard Collection Kit |
| Intra-Sana Laboratories | $19.26 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Redhill Biopharma INC. | $19.15 | 2023 | Aemcolo, Talicia, Movantik |
| Regeneron Healthcare Solutions, INC. | $14.47 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Macaela Cirish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.